As for other mobilizing chemotherapy regimens, ID-AraC plus G-CSF SD significantly impproved mobilization efficacy over G-CSF SD alone in patients with MM, RCT comparing the other chemotherapy regimens plus G-CSF with G-CSF alone is not available [30]. This evidence concerns the gene CSF3 and Miyoshi myopathy.